Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Solara Active Pharma Sciences Ltd., often referred to simply as Solara, is a dynamic and innovative pharmaceutical company headquartered in India. Specialising in Pharmaceutical Preparation Manufacturing, Solara plays a crucial role in the global healthcare ecosystem, providing essential ingredients for life-saving medicines.
Established in 2017, Solara quickly carved out a significant niche by focusing on the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and API intermediates. Their core strength lies in a diverse portfolio of high-quality, cost-effective products spanning various therapeutic areas, making them a preferred partner for pharmaceutical giants worldwide.
Leveraging advanced R&D capabilities and state-of-the-art manufacturing facilities, Solara maintains a strong commitment to quality and regulatory compliance. This dedication has solidified their position as a leading API manufacturer, contributing significantly to global health initiatives.
-10 vs industry average
Solara Active Pharma Sciences Ltd’s score of 32 is lower than 44% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
In 2025, Solara Active Pharma Sciences Ltd reported total emissions of approximately 41,178,000 kg CO2e, comprising 12,118,000 kg CO2e from Scope 1 and 28,660,000 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data.
Solara is committed to achieving net-zero emissions, as indicated by their near-term target status of "Committed." This commitment aligns with their operations in the Pharmaceuticals, Biotechnology, and Life Sciences sector, based in India.
Over the past few years, emissions have fluctuated, with 2024 emissions recorded at approximately 77,112,000 kg CO2e (33,489,000 kg CO2e from Scope 1 and 43,622,000 kg CO2e from Scope 2) and 2023 emissions at approximately 54,430,000 kg CO2e (11,168,000 kg CO2e from Scope 1 and 43,425,000 kg CO2e from Scope 2).
The company has not set specific reduction targets but remains focused on its long-term climate commitments. As of now, there are no emissions data cascaded from a parent or related organization.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Solara Active Pharma Sciences Ltd’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more